Materials Design Analysis Reporting (MDAR) Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where provided:	n/a
For commercial reagents, provide supplier name, catalogue number and		NA (didn't use any antibodies)

Cell materials	Yes (indicate where provided:	n/a
Cell lines: Provide species information, strain. Provide accession number in repository **OR** supplier name, catalog number, clone number, **OR** RRID		NA (didn't use any cell lines)
Primary cultures: Provide species, strain, sex of origin, genetic modification		NA (didn't use any primary culture)

Experimental animals	Yes (indicate where provided:	n/a
Laboratory animals: Provide species, strain, sex, age, genetic modification status. Provide accession number in repository **OR** supplier name, catalog number, clone number, **OR** RRID		NA (didn't use any animals)
Animal observed in or captured from the field: Provide species, sex and age where possible		NA (didn't use any animals)
Model organisms: Provide Accession number in repository (where relevant)		NA (didn't use any organisms)

Plants and microbes	Yes (indicate where provided:	n/a
Plants: provide species and strain, unique accession number if available, and source (including location for collected wild		NA (didn't use any plants)
Microbes: provide species and strain, unique accession number if available,		NA (didn't use any microbes)

Human research participants	Yes (indicate where provided:	n/a
Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	**This study was approved by the Medical Ethics Committee of Xinqiao Hospital, the Third Military Medical University.**	
Provide statement confirming informed consent obtained from study participants.	**All patients or guardians signed informed consent forms (Registration No: ChiCTR-OCH-12002744)**	
Report on age and sex for all study participants.	**It has been shown as Figure 3A in the manuscript.**	

Design

Study protocol	Yes (indicate where provided:	n/a
For clinical trials, provide the trial registration number **OR** cite DOI in manuscript.		NA (our study is not a clinical trials)

Laboratory protocol	Yes (indicate where provided:	n/a
Provide DOI or other citation details if detailed step-by-step protocols are available.		NA (didn't invovle lab experiments)

Experimental study design (statistics details)	Yes (indicate where provided:	n/a
State whether and how the following have been done**, or** if they were not carried out.		
Sample size determination	1234 patients (page 5,line 4)	
Randomisation	12 hospitals in Chongqing	
Blinding	All are outpatients	
Inclusion/exclusion criteria	Death (page 5,line 5)	

Sample definition and in-laboratory	Yes (indicate where provided:	n/a
State number of times the experiment was replicated in laboratory		NA (didn't invovle lab experiments)
Define whether data describe technical or biological replicates	929 newly diagnosed patients and 294 previously diagnosed	

Ethics	Yes (indicate where provided:	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Clinical review Number 2012012 in Third Military Medical University	
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.		NA (didn't invovle animals)
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.		NA (didn't invovle specimen and field samples)

Dual Use Research of Concern (DURC)	Yes (indicate where provided:	n/a
If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory		NA (it's not subject to dual use research of concern)

Analysis

Attrition	Yes (indicate where provided:	n/a
State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance.	See Figure 1 (page 17)	

Statistics	Yes (indicate where provided:	n/a
Describe statistical tests used and justify choice of tests.	See "Methods" (page 4)	

Data Availability	Yes (indicate where provided:	n/a
State whether newly created datasets are available, including protocols for access or restriction on access.		NA (didn't creat any new datasets)
If data are publicly available, provide accession number in repository or DOI or URL.		NA (there's no available public database for our data type)
If publicly available data are reused, provide accession number in repository or DOI or URL, where possible.		NA (no public data are reused in our study)

Code Availability	Yes (indicate where provided:	n/a
For all newly generated code and software essential for replicating the main findings of the study:		
State whether the code or software is available.		NA (no new code generated)
If code is publicly available, provide accession number in repository, or DOI or URL.		NA (no new code generated)

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (eg., CONSORT, PRISMA, ARRIVE) is provided with the manuscript.	ICMJE guidelines were followed, as the journal follows ICMJE recommendations for publication.	

Article information: http://dx.doi.org/10.21037/apm-20-1741